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Biginelli dihydropyrimidinone derivatives as structural analogs of monastrol, a known human kinesin Eg5 inhibitor,
were synthesized. IC50 values of the synthesized compounds against the proliferation of human hepatocellular
carcinoma and human epithelial carcinoma cell lines were determined through MTT assay. Molecular docking study
gave a clear insight into the structural activity relationship of the compounds in comparison with monastrol.
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1,4-Dihydropyrimidinones (DHPMs) comprise of a pyr-
imidine scaffold having a resemblance with the struc-
tures of the nucleic acid bases found in DNA and RNA.
Their involvement as bases in nucleic acids has a great
significance in drug design. Recent progress in the
DHPM class of the anticancer agent monastrol, an in-
hibitor of human kinesin Eg5 [1,2], has led to the atten-
tion for efficient pharmacophore variation of Biginelli
DHPMs. Human kinesin Eg5 plays a crucial role in bipo-
lar spindle generation during mitosis, inhibition of which
leads to mitotic arrest and subsequent apoptotic cell
death [3]. It is therefore considered as one of the prom-
ising targets in cancer chemotherapy. Racemic dihydro-
pyrimidinone is reported to be an allosteric inhibitor of
Eg5 [4], and unlike taxanes, it is nontoxic to neuron
cells [5,6].
Considerable work has also been devoted to gain
insights into the structure-activity relationship in the
monastrol derivative series [7]. Recently, Dennis
Russowsky and coworkers described the differential effects
of monastrol, oxo-monastrol and oxygenated analogs on
seven human cancer cell lines [8]. However, anticancer* Correspondence: uttarasn@gmail.com
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reproduction in any medium, provided the origactivity profile of amide derivatives of dihydropyrimidi-
nones with functional variations at aromatic ring has not
been explored so far. This paper describes the synthesis
and evaluation of monastrol-related racemic dihydropyri-
midinones substituted with privileged structures [9] like
pyrrolidine, piperidine and morpholine through an amide
linkage. It was speculated that the introduction of cyclic
amines through amide linkage at the side chain of the
DHPM scaffold could mimic the interactions of the ester
group of monastrol and might also provide improved
metabolic stability to the moiety. In order to probe the
effect of substitutions at the aromatic ring of Biginelli
DHPMs on cytotoxicity, halogens were introduced at
ortho and para positions. Physicochemical properties and
biological activity of thiourea is closely related with urea,
which possesses bioisosteric pharmacophore groups.
Hence, thiourea motif of the DHPMs has been replaced
by urea that may function as a bioisoster. In addition, the
molecular docking and virtual physicochemical properties
were studied to understand the structural activity relation-
ship of the scaffold.Methods
Chemistry
General remarks
Melting points were taken in capillary tubes, measured
in the melting point apparatus and were uncorrected.ger. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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http://www.orgmedchemlett.com/content/2/1/23Infrared spectra were recorded on a Shimadzu FTIR 8310
spectrometer. Nuclear magnetic resonance (NMR) spectra
were recorded on Bruker 400/500 MHz spectrometer in
CDCl3/DMSO-d6/CD3OD. Chemical shifts are reported
in parts per million (ppm) from tetramethylsilane with tet-
ramethylsilane as the internal standard. Data reported
are as follows: chemical shift, multiplicity as singlet (s),
doublet (d), triplet (t), quartet (q), broad singlet (br s)
and multiplet (m), and coupling constants (Hz). Mass
spectra were obtained on a Shimadzu GCMS-QP5050A.
Combustion analyses were performed on a Perkin-Elmer
2400-II analyzer. The progress of the reactions was moni-
tored by thin layer chromatography using F254 silica gel
pre-coated sheets (Merck, India). Column chromatog-
raphy was performed on silica gel (100 to 200 mesh).
Solvents for extraction and chromatography were AR/
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Scheme 1 Synthetic scheme for the preparation of compounds 3a toGeneral method for the preparation of compounds 1a
to 1d
A solution of arylaldehyde (0.28 mmol), ethyl acetoacetate
(0.28 mmol), urea (0.42 mmol) and boric acid
(0.056 mmol) in glacial acetic acid (15 mL) was heated at
100°C, stirring for 9 h. Progress of the reaction was moni-
tored by thin layer chromatography (TLC) using hexane:
ethyl acetate (4:6) as mobile phase. Then, the reaction
mixture was cooled to room temperature, poured into ice-
cold water (150 to 200 mL) and stirred for 15 min. The
solid precipitate obtained was filtered, washed with ice-
cold water and recrystallized with absolute alcohol to af-
ford white solid crystals with a quantitative yield [10].
Ethyl 4-methyl-2-oxo-6-phenylhexahydropyrimidine-5-
carboxylate (1a): Colorless crystals, Yield 80%. Melting
point (Mp.) 200°C to 202°C (Literature (Lit.) [11] Mp.
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1,645 (C=O str.). 1H NMR (500 MHz, DMSO-d6): δ 9.21
(s, 1 H), 7.46 (br s, 1 H), 7.35 to 7.14 (m, 5 H), 5.62 (s, 1 H),
3.95 (q, 2 H), 2.26 (s, 3 H), 0.997 (s, 3 H).
Ethyl 4-(4-fluorophenyl)-6-methyl-2-oxohexahydropyri-
midine-5-carboxylate (1b): Colorless crystals, Yield 80%.
Mp. 178°C to 180°C (Lit. [12] Mp. 175°C to 177°C). Rf
0.51 (Hexane:ethyl acetate (4:6)). IR (KBr) cm−1: 3,242
(N-H str.), 1,718 (C =O str.), 1,645 (C =O str.). 1H
NMR (500 MHz, DMSO-d6): δ 9.38 (s, 1 H), 7.86 (br s,
1 H), 7.46 to 7.36 (m, 2 H), 7.33 to 7.24 (m, 2 H), 5.56
(s, 1 H), 3.96 (q, 2 H), 2.27 (s, 3 H), 1.03 (s, 3 H).
Ethyl 4-(4-chlorophenyl)-6-methyl-2-oxohexahydropyri-
midine-5-carboxylate (1c): Colorless crystals, Yield 81%.
Mp. 214°C to 216°C. (Lit. [13] Mp. 214°C to 217°C). Rf
0.54 (Hexane:ethyl acetate (4:6)). IR (KBr) cm−1: 3,350
(N-H str.), 1,637 (C =O str.). 1 H NMR (500 MHz,
DMSO-d6): δ 9.57 (s, 1 H), 7.76 (br s, 1 H), 7.43 to 7.38
(m, 2 H), 7.34 to 7.21 (m, 2 H), 5.68 (s, 1 H), 3.87 (q, 2 H),
2.33 (s, 3 H), 0.995 (s, 3 H).
Ethyl 4-(2-chlorophenyl)-6-methyl-2-oxohexahydropyri-
midine-5-carboxylate (1d): Colorless crystals, Yield 78%.
Mp. 213°C to 215°C. (Lit. [14] Mp. 212.5°C to 214.5°C).
Rf 0.55 (Hexane:ethyl acetate (4:6)). IR (KBr) cm
−1: 3,350
(N-H str.), 1,637 (C =O str.). 1 H NMR (500 MHz,
DMSO-d6): δ 9.27 (s, 1 H), 7.71 (br s, 1 H), 7.40 (d,
1 H), 7.34 to 7.29 (m, 2 H), 7.28 to 7.25 (m, 1 H), 5.63
(s, 1 H), 3.91 (q, 2 H), 2.3 (s, 3 H), 0.998 (s, 3 H). MS (EI):
295 [M]+.
General method for the preparation of compounds 2a
to 2d
A solution of compounds 1a to 1d (2 mmol) in 10 mL
methanol and NaOH (4 mmol) dissolved in 1 mL water
was heated at 60°C to 62°C, stirring for 8 h. Progress of
the reaction was monitored by TLC using chloroform:
methanol (9:1) as mobile phase. The reaction mixture
was cooled and concentrated under vacuum to remove
methanol. The residue obtained was then added to
25 mL ice-cold water and was extracted with chloroform
(3 × 10 mL) to remove the unreacted ester. The aqueous
layer was acidified to pH 2 using 10% v/v HCl and then
extracted with ethyl acetate (3 × 15 mL). The ethyl acet-
ate layer was separated, pooled over anhydrous sodium
sulfate and evaporated under vacuum to give the crude
acid. The crude acid was purified by column chromatog-
raphy using chloroform:methanol (95:5) as mobile phase
and silica gel (100 to 200 mesh) as stationary phase to
afford the pure product [15-17].
4-Methyl-2-oxo-6-phenylhexahydropyrimidine-5-car-
boxylic acid (2a): Colorless solid, Yield 35%. Mp. 217°C
to 219°C. (Lit. [18] Mp. 210°C). Rf 0.26 (Chloroform:
methanol (9:1)). IR (KBr) cm−1: 3,431 (O-H str.), 3,225
(N-H str.), 1,645 (C =O str.), 1,705 (C =O str.).4-(4-Fluorophenyl)-6-methyl-2-oxohexahydropyrimidine-
5-carboxylic acid (2b): Colorless solid, Yield 36%. Mp.
200°C to 202°C. Rf 0.28 (Chloroform:methanol (9:1)). IR
(KBr) cm−1: 3,442 (O-H str.), 3,227 (N-H str.), 1,705
(C =O str.).
4-(4-Chlorophenyl)-6-methyl-2-oxohexahydropyrimidine-
5-carboxylic acid (2c): Colorless solid, Yield 38%. Mp.
207°C to 209°C (Lit. [18] Mp. 199°C to 200°C). Rf 0.24
(Chloroform:methanol (9:1)). IR (KBr) cm−1: 3,439 (O-H
str.), 3,238 (N-H str.), 1,643 (C =O str.).
4-(2-Chlorophenyl)-6-methyl-2-oxohexahydropyrimidine-
5-carboxylic acid (2d): Colorless solid, Yield 37%. Mp.
212°C to 214°C. Rf 0.27 (Chloroform:methanol (9:1)). IR
(KBr) cm−1: 3,444 (O-H str.), 3,238 (N-H str.), 1,708
(C=O str.), 1,645 (C=O str.). 1H NMR (500 MHz,
CD3OD): δ 7.42 to 7.40 (dd, 2 H, J= 7.5 and 1.5 Hz), 7.36
to 7.34 (dd, 1 H, J=8 and 2 Hz), 7.32 to 7.30 (dd, 1 H,
J=7.5 and 1.5 Hz), 7.27 to 7.26 (d, 1 H, J=1.5 Hz), 5.83
(s, 1 H), 2.18 (s, 3 H). ESI-MS, 266.5 [M]+.
General method for the preparation of compounds 3a
to 3 l
A mixture of compounds 2a to 2d was added to tetra-
methyluronium tetraflouroborate (TBTU) (1.5 eq.) and dii-
sopropylethylamine (2 eq.) in 2 mL dimethylformamide
under nitrogen atmosphere. The mixture was stirred for
2 min at 25°C, and then, pyrrolidine/piperidine/morpholine
(1.5 eq., 0.068 mL) was added to it. Another 2 equivalents
of diisopropylethylamine (DIPEA) was again added to it.
The reaction mixture was stirred for 10 min. The reaction
was monitored by TLC using chloroform:methanol (9:1).
The reaction mixture was poured into 50 mL ice-cold water
and was extracted with dichloromethane (3×20 mL). The
extract was purified by column chromatography using
chloroform:methanol (97:3) and silica gel (100 to 200 mesh)
as stationary phase to afford the desired product [19,20].
6-Methyl-4-phenyl-5-(pyrrolidine-1-carbonyl)-3,4-dihy-
dropyrimidin-2(1 H)-one (3a): White solid, Yield 81%.
Mp. 258°C to 260°C. Rf: 0.46 (Chloroform:methanol
(9:1)). IR (KBr) cm−1: 3,224, 3,145 (N-H str.), 1,696
(C =O str.), 2,881 (C-H str.). 13 C NMR (400 MHz,
DMSO-d6): δ 166.34 (C =O), 161.83 (C =O), 140.42 to
124.32 (6 C, aromatic), 151.74 (=C-NH), 25.32 to 23.96
(4 C, aliphatic), 15.56 (CH3).
1 H NMR (400 MHz,
CDCl3): 7.26 to 7.24 (m, 5 H), 6.38 (br s, 1 H), 5.41
(s, 1 H), 5.11 (s, 1 H), 3.26 to 2.10 (m, 8 H), 1.73









pyrimidin-2(1 H)-one (3b): White solid, Yield 83%. Mp.
266°C to 268°C. Rf 0.49 (Chloroform:methanol (9:1)). IR
(KBr) cm−1: 3,223, 3,095 (N-H str.), 1,681 (C =O str.),
2,858 (C-H str.). 13 C NMR (400 MHz, DMSO-d6):
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aromatic), 152.26 (=C-NH), 104.48, 56.24 (CH), 26.32 to
23.80 (5 C, aliphatic), 15.78 (CH3).
1H NMR (400 MHz,
CDCl3): δ 8.44 (br s, 1 H), 7.35 (s, 1 H, aromatic H),
7.33 (d, 1 H, J= 0.8 Hz), 7.31 (t, 1 H, J= 2.4 Hz), δ 7.26
(m, 1 H), 7.19 (d, 1 H, J= 0.8 Hz), 7.17 (s, 1 H), 2.95 (s,









pyrimidin-2(1 H)-one (3c): White solid, Yield 83%. Mp.
233°C to 234°C. Rf 0.52 (Chloroform:methanol (9:1)). IR
(KBr) cm−1: 3,240 (N-H str.), 1,695 (C=O str.), 2,858 (C-
H str.). 13C NMR (400 MHz, DMSO-d6): 166.68 (C=O),
162.28 (C=O), 142.28 to 126.23 (6 C, aromatic), 152.38
(=C-NH), 103.76, 56.22 (CH), 30.42 to 26.68 (4 C, ali-
phatic), 15.32 (CH3).
1H NMR (400 MHz, CDCl3): δ 7.35
to 7.31(m, 5 H) 7.21 (d, 1 H, J=1.6 Hz) 5.49 (s, 1 H), 5.30
(s, 1 H), 3.22 to 3.05 (m, 6 H) 1.27 to 1.29 (m, 2 H). MS








4-dihydropyrimidin-2(1 H)-one (3d): White solid, Yield
80%. Mp. 242°C to 244°C. Rf 0.48 (Chloroform:methanol
(9:1)). IR (KBr) cm−1: 3,242, 3,142 (N-H str.), 1,689, 1,660
(C=O str.), 2,954 (C-H str.). 13 C NMR (400 MHz,
DMSO-d6): δ 166.57 (C=O), 160.15 (C=O), 162.15 to 114
(6 C aromatic), 152.58 (=C-NH), 105.79, 55.6 (CH), 25.11
to 23.80 (4 C, aliphatic), 15.96 (CH3).
1H NMR (400 MHz,
CDCl3): 7.26 to 6.29 (m, 4 H), 6.87 (br s, 1 H), 5.41
(s, 1 H), 5.23 (s, 1 H), 3.26 to 2.59 (m,4 H), 1.67 (s, 3 H),









4-dihydropyrimidin-2(1 H)-one (3e): White solid, Yield
82%. Mp. 264°C to 266°C. Rf: 0.53 (Chloroform:methanol
(9:1)). IR (KBr) cm−1: 3,240 (N-H str), 1,691 (C =O str),
1,658 (amide C=O str). 13 C NMR (400 MHz, DMSO-
d6): δ 165.76 (C =O), 160.52 (C =O), 163.18 to 113.32
(6 C, aromatic), 153.26 (=C-NH), 106.72, 55.4 (CH),
26.52 to 23.20 (5 C, aliphatic), 15.40 (CH3).
1H NMR
(400 MHz, CDCl3): δ 7.55 (s, 1 H), 7.35 to 7.30
(m, 2 H,), 7.05 to 7.01 (m, 2 H), 5.45 (s, 1 H), 5.43
(s, 1 H), 3.86 to 3.04 (m, 4 H), 1.76 (s, 3 H), 1.60 to 1.55
(m, 2 H), 1.46 to 1.41 (m, 2 H), 1.29 to 1.24(m, 2 H). MS










4-dihydropyrimidin-2(1 H)-one (3f): White solid, Yield
82%. Mp. 230°C to 232°C. Rf 0.51 (Chloroform:methanol
(9:1)). IR (KBr) cm−1: 3,248, 3,150 (N-H str.), 1,681, 1,608
(C =O str.), 2,875 (C-H str.). 13 C NMR (400 MHz,DMSO-d6): δ 166.22 (C =O), 161.36 (C =O), 162.78 to
113.76 (6 C, aromatic), 152.64 (=C-NH), 105.63, 55.28
(CH), 29.22 to 24.46 (4 C, aliphatic), 15.63 (CH3).
1H
NMR (400 MHz, CDCl3): 7.27 to 6.96 (m, 4 H), 6.41
(s,1 H), 5.42 (s, 1 H), 5.10 (s, 1 H), 3.25 to 3.027 (m, 4 H),









3,4-dihydropyrimidin-2(1 H)-one (3 g): White solid,
Yield 84%. Mp. 260°C to 262°C. Rf 0.42 (Chloroform:
methanol (9:1)). IR (KBr) cm−1: 3,227, 3,151(N-H str.),
1,676, 1,608 (C=O str.), 2,862 (C-H str.). 13C NMR
(400 MHz, DMSO-d6): δ 165.82 (C=O), 162.28 (C=O),
139.70 to 115.92 (6 C, aromatic), 153.72 (+C-NH), 103.02,
56.75 (CH), 24.78 to 23.20 (4 C, aliphatic), 15.34 (CH3).
1H NMR (400 MHz, CDCl3): δ 7.55 (br s, 1 H), 7.32 to
7.29 (m, 2 H,), 7.28 to 7.26 (m, 2 H), 5.44 (s, 1 H), 5.46
(s, 1 H), 3.33 (s, 2 H), 3.02 (s, 1 H), 2.68 (s, 1 H), 1.80






3,4-dihydropyrimidin-2(1 H)-one (3 h): White solid, Yield
86%. Mp. 253°C to 255°C. Rf 0.48 (Chloroform:methanol
(9:1)). IR (KBr) cm−1: 3,227, 3,151(N-H str.), 1,676, 1,608
(C =O str.), 2,862 (C-H str.). 13 C NMR (400 MHz,
DMSO-d6): δ 166.25 (C =O), 161.48 (C =O), 138.78 to
116.26 (6 C, aromatic), 152.58 (=C-NH), 103.38, 56.53
(CH), 25.20 to 23.64 (5 C, aliphatic), 15.62 (CH3).
1H
NMR (400 MHz, CDCl3): δ 7.70 (br s, 1 H), 7.32 to 7.24
(m, 4 H), 3.48 to 3.02 (m, 4 H), 1.79 (s, 3 H), 1.66 to









3,4-dihydropyrimidin-2(1 H)-one (3i): White solid, Yield
84%. Mp. 228°C to 230°C. Rf 0.44 (Chloroform:methanol
(9:1)). IR (KBr) cm−1: 3,264, 3,102 (N-H str.), 1,681, 1,624
(C=O str.), 2,858 (C-H str.). 13C NMR (400 MHz,
DMSO-d6): 165.62 (C=O), 162.36 (C=O), 139.28 to
116.44 (6 C, aromatic), 152.76 (=C-NH), 104.28, 56.24
(CH), 29.76 to 24.38 (4 C, aliphatic), 15.78 (CH3).
1H
NMR (400 MHz, CDCl3): 7.28 to 7.20 (m, 4 H), 7.04 (br s,
1 H), 5.41 (s, 1 H), 5.27 (s, 1 H), 3.25 to 3.03 (m, 6 H),









4-dihydropyrimidin-2(1 H)-one (3j): White solid, Yield 83%.
Mp. 223°C to 224°C. Rf 0.53 (Chloroform:methanol (9:1)).
IR (KBr) cm−1: 3,221, 3,095 (N-H str.), 1,686 (C=O str.),
2,877 (C-H str.). 13C NMR (400 MHz, DMSO-d6): 166.24
(C=O), 162.36 (C=O), 150.25 (=C-NH), 143.66 to 121.54
(6 C, aromatic), 105.65, 53.44 (CH), 26.28 to 23.93 (4 C,
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1H NMR (400 MHz, CDCl3): δ 7.52
to 7.50 (dd, 1 H, J=7.6 and 1.6 Hz), 7.34 to 7.32 (dd, 1 H,
J=7.6 and 1.2 Hz,), 7.30 to 7.23 (dd, 1 H, J=7.6 and 1.6 Hz),
7.22 to 7.20(dd, 1 H, J=7.6 and 1.6 Hz,), 6.91 (br s, 1 H),
5.76 (d, 1 H, J=1.2 Hz), 5.36 (s, 1 H), 3.37 to 3.20 (m, 4 H),
1.89 (d, 4 H, J=0.4 Hz), 1.79 (s, 3 H). MS (EI): 319 [M]+,
304 [M-CH3]






3,4-dihydropyrimidin-2(1 H)-one (3 k): White solid, Yield
80%. Mp. 240°C to 242°C. Rf 0.52 (Chloroform:methanol
(9:1)). IR (KBr) cm−1: 3,222, 3,109 (N-H str.), 1,685 (C=O
str.), 2,949 (C-H str.). 13C NMR (400 MHz, DMSO-d6):
166. 38 (C=O), 161.72 (C=O), 141.56 to 122.38 (6 C, aro-
matic), 151.36 (=C-NH), 104.72, 54.46 (CH), 25.92 to
23.80 (5 C, aliphatic), 15.55 (CH3).
1H NMR (400 MHz,
CDCl3): 7.49 to 7.48 (d, 1 H, J= 7.2 Hz), 7.43 (s, 1 H), 7.35
to 7.33 (d, 1 H, J=6.8 Hz), 7.28 (t, 1 H, J=3.6 Hz), 7.24 to
7.22 (dd, 1 H, J=1.6 and 7.6 Hz), 5.74 (s, 1 H), 5.40 (s,
1 H), 3.35 to 3.21 (m, 4 H), 1.84 (s, 3 H), 1.49 to 1.33 (m,








3,4-dihydropyrimidin-2(1 H)-one (3 l): White solid, Yield
80%. Mp. 240°C to 242°C. Rf 0.52 (Chloroform:methanol
(9:1)). IR (KBr) cm−1: 3,240, 3,099 (N-H str.), 1,685(C=O
str.), 2,860 (C-H str.). 13C NMR (400 MHz, DMSO-d6):
165.42 (C=O), 161.56 (C=O), 140.49 to 121.25 (6 C, aro-
matic), 153.25 (=C-NH), 104.72, 54.72 (CH), 28.56 to
24.78 (4 C, aliphatic), 15.45 (CH3).
1H NMR (400 MHz,
CDCl3): 7.47 (br s, 1 H), 7.40 to 7.38 (dd, 1 H, J= 1.6 and
7.6 Hz), 7.31 to 7.18 (dd, 1 H, J= 1.6 and 7.6 Hz), 7.24 to
7.22 (dd, 1 H, J=1.6 and 7.2 Hz), 7.20 to 7.18 (m, 2 H),









In order to assess the in vitro cytotoxicity potential of these
monastrol mimics, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay on HepG2 and HeLa
cell lines was performed. Exponentially growing cell lines
were harvested from 25 cm2. Tissue culture flasks and a
stock cell suspension (1×105 cell/mL) were prepared. A
96-well flat-bottom tissue culture plate was seeded with
1×104 cells in 0.1 ml of MEM and DMEM mediums sup-
plemented with 10% FBS and allowed to attach for 24 h.
Test compounds were prepared just prior to the experi-
ment in 0.5% DMSO and serially diluted with medium to
get the working stock of 500, 250, 125 and 62.5 μg/mL so-
lution. After 24 h of incubation, cells were treated with 20
μL of test solutions from the respective top stocks, 80 μL of
fresh medium was added, and the cells were incubated for48 h. The cells in the control group received only the
medium containing 0.5% DMSO. Each treatment was per-
formed in triplicates. After the treatment, the drug-
containing media was removed and washed with 200 μL of
phosphate buffered saline (PBS). To each well of the 96-
well plate, 100 μL of MTT reagent (stock, 1 mg/mL in
PBS) was added and incubated for 4 h at 37°C. After 4 h of
incubation, the plate was inverted on tissue paper to re-
move the MTT reagent. To solubilize formazan crystals in
the wells, 100 μL of 100% DMSO was added to each well.
The optical density was measured by an enzyme-linked im-
munosorbent assay plate reader at 540 nm [21].Molecular modeling
Molecular modeling studies were performed using a flex-
ible docking method with the Glide version 2010 as
described by Yan et al. [22] and Garcia-Saez et al. [23]. The
X-ray crystal structure of Eg5 complexed with monastrol
(Protein Data Bank ID: 1Q0B) was retrieved from the Pro-
tein Data Bank. The three-dimensional structures of the
DHPM derivatives were constructed with the Chemdraw
Ultra 8.0. Energy minimizations were performed by Lig-
prep using OPLS-2004 force field. The binding affinity of
the inhibitors to the protein was then evaluated by the total
glide docking energies. The physicochemical properties of
the compounds, such as molecular weight, log P, hydrogen
bond acceptors/donors, polar surface area (PSA) and num-
ber of rotatable bonds of the synthesized compounds, were
calculated using QuikPro (Schrodinger-2010).Results and discussion
Chemistry
The dihydropyrimidinones in this study were prepared by
the Biginelli reaction [24] of the substituted benzaldehyde,
urea and ethylacetoacetate depicted in Scheme 1. Interest-
ingly, the hydrolysis of DHPM was much slower and
stalled at less than 10% conversion. A substantial amount
of decarboxylated product was formed during hydrolysis,
similar to the earlier reports [7]. Since a simultaneous de-
carboxylation accompanied the formation of acid, it was
found that the temperature and reaction time played a
crucial role in the productivity of the reaction.
Since mild hydrolyzing agent could prevent the extent
of decarboxylation, lithium hydroxide with different
solvent combinations (methanol/THF/dioxane) [25] was
used for hydrolysis. The reaction was found to proceed
slowly, along with the formation of lesser decarboxylated
product, but also resulted in low yields of acid (>20%).
Earlier literature reports of DHPM esters hydrolysis in
ethyl acetate and sodium hydroxide (25°C to 27°C, 2 h)
[26] also failed to form the acid. The ester did not
proceed to form the acid even after refluxing with ethyl
acetate for 12 h.
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reflux) also failed to yield any acid. Refluxing with KOH
and ethanol led to decarboxylation due to higher refluxing
temperature (around 80°C). These observations propelled
us to use a solvent with a lower boiling point.
Studies also reported that refluxing in methanol in the
presence of aqueous NaOH (10%) led to hydrolysis and
consequent decarboxylation [16,17]. Hence, the opti-
mized method for hydrolysis involved heating the ester
in methanol with aqueous NaOH at 60°C to 62°C for
8 h. Prolongation of the reaction time or increase in
temperature resulted in decarboxlyation. However, it
was observed that higher quantities of NaOH did not
affect the decarboxylation process.
The synthesis of compounds 3a to 3 l with a stable amide
linker between DHPMs and cyclic amines was achieved via
TBTU/DIPEA-promoted coupling reaction, which was
quick and high yielding. The physical data of all the synthe-
sized compounds are summarized in Table 1. The mass,
proton and carbon NMR spectra of some of the finalTable 1 Structural details and percentage yield of compound
Compound
code





















R, substitution on the phenyl ring; R1, substituted cyclic amine (as depicted in Schecompounds synthesized can be found in Additional files 1,
2, 3, 4, 5, 6, 7 and 8.
Cytotoxicity studies
The data obtained from in vitro cytotoxicity assay suggest
that compounds 3 g and 3 h were found to be the most
potent against the HepG2 cell lines with IC50 124.46 and
120.62 μg/mL, respectively. However, most of the com-
pounds exhibited weak activity (IC50 200 μg/mL) against
HeLa cell lines. Hence, it was anticipated that substitution
of electron-withdrawing substituents, such as chlorine,
at the para position may be essential for the ligand-
receptor interaction. Structure-activity relationship (SAR)
analysis revealed that compounds with weakly basic
pyrrolidine and piperidine substitution in the side chain
attenuate the anticancer activity. In contrast, morpholine
was not tolerated at the side chain of DHPMs and hence
resulted in decreased IC50. Molecular modeling studies
showed the absence of hydrogen bonding interactions
with Glu-118, which could be attributed to the missings 3a to 3 l
Compound
code
































3 g 124 187
3 h 120 217
3i 218 374
3j 192 261
3 k 191 398
3 l 218 374
a50% inhibitory concentration. HepG2, human hepatocellular carcinoma; HeLa,
human epithelial carcinoma.
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bonding interactions of water molecules with the oxygen
atom of morpholine in compounds 3c, 3f, 3i and 3 l
proved to be fatal for anticancer activity. In vitro data for
these compounds are summarized in Table 2. Figure 1
shows the schematic view of the contacts of S-monastrol
and compound 3 h with the residues of Eg5 inhibitor-
binding pockets with in 3 Å, and hydrogen bonds are
depicted by dashed lines.Structure-activity relationship
To determine the SAR, functionality modification was car-
ried out on the phenyl ring, while different cyclic amines
were introduced at the side chain of DHPMs. Unsubstituted
compounds (3a, 3b and 3c) which displayed IC50 of 180.92,Figure 1 S-monastrol and compound 3 h.166.96 and 207.45 μg/mL and 216, 189 and 240 μg/mL
against HePG2 and HeLa cell lines, respectively, served
as the template for cytotoxicity potential comparison.
Replacement of the protons in compounds 3a, 3b and
3c with fluorine at the para position of the phenyl ring
did not improve the cytotoxicity against both cell lines.
However, compound 3d showed a better IC50 (178 μg/mL)
than its analog 3a against HepG2 cell lines. Encouraged
by this result, fluorine was replaced by chlorine at the
same position on the phenyl ring in compounds 3d, 3e
and 3f to afford compounds 3 g, 3 h and 3i. Surprisingly,
compound 3 g and 3 h significantly inhibited the prolif-
erations of HepG2 cell lines with IC50 of 124.46 and
120.62 μg/mL. The anticancer activities of these two
compounds against HeLa cell lines were equally frustrat-
ing like the previous results. The possibility to change the
position of chlorine from para to ortho in the phenyl ring
was then explored. Interestingly, this modification proved
detrimental, and compounds 3j, 3 k and 3 l displayed IC50
of 190 μg/mL.Molecular modeling
In order to further investigate the relationships between
the virtual receptor-ligand binding interaction and physi-
cochemical properties of the new compounds with their
anticancer activity, molecular modeling studies were per-
formed. Docking analysis revealed that hydrogen bond
formation and hydrophobic interactions were the key
factors affecting inhibitory action of the compounds.
The Glu-116, Gly-117, Glu-118, Ar-119, Trp-127, Pro-
137, Tyr-211 and Leu-214 of Eg5 protein were found to
be directly interacting with the synthesized DHPMs.
Most of the synthesized compounds showed hydrogen
bonding interaction with Glu-116 as monastrol. How-
ever, the unsubstituted compounds, except 3c (Figure 2),
Figure 3 Monastrol with Eg5 protein (1Q0B). The yellow dotted lines represent hydrogen bonding interaction.
Figure 2 Compound 3c with Eg5 protein (1Q0B).
Soumyanarayanan et al. Organic and Medicinal Chemistry Letters 2012, 2:23 Page 8 of 11
http://www.orgmedchemlett.com/content/2/1/23
Table 3 In silico docking results
Compound Docking
scorea
H-bonding with Glu-116 H-bonding with Glu-118
Distance (Å) Energy (Kcal/mol) Distance (Å) Energy (Kcal/mol)
Monastrol −9.780843 2.022 −0.25495 1.800922 −0.25495
3a −4.623578 1.794177 0 1.91532 0
3b −4.099871 2.087333 0 2.437469 0
3c −7.66649 2.184935 −0.155458 2.543947 0
3d −3.518203 2.579143 −0.092150 2.579143 0
3e −7.396385 2.231526 −0.123687 2.472871 0
3f −3.336005 2.365419 −0.097571 2.477461 0
3 g −8.667402 2.226021 −0.076754 2.496712 0
3 h −7.541568 1.947079 −0.215195 2.240761 0
3i −6.983773 2.04085 −0.226944 2.243988 0
3j −7.419477 2.224107 −0.171504 2.25015 0
3 k −6.988692 2.242662 −0.124171 2.197052 0
3 l −6.8606 2.266054 −0.068286 2.199539 0
aGrid scoring from flexible docking (kcal/mol).
Table 4 In silico physicochemical properties predictiona
Compound Mol. Wt. Log P H donor H acceptor Rot. bonds PSA (Å2)
Monastrol 292.352 3.31 1 3.25 3 85.118
3a 285.345 3.406 0 3 1 78.312
3b 299.372 3.681 0 3 1 77.135
3c 301.344 2.533 0 4.7 1 86.394
3d 303.335 3.67 0 3 1 78.367
3e 319.335 2.818 0 3 1 77.133
3f 317.362 3.919 0 4.7 1 86.585
3 g 319.79 3.925 0 3 1 78.307
3 h 333.817 4.092 0 3 1 76.989
3i 335.789 3.083 0 4.7 1 86.586
3j 319.79 3.761 0 3 1 77.458
3 k 333.817 3.812 0 3 1 75.797
3 l 335.789 2.897 0 4.7 1 86.938
aQikProp v3.4 (Schrodinger-2010). H donor, hydrogen bond donor; H acceptor,
hydrogen bond acceptor; Mol. Wt., molecular weight; Rot. bonds, number of
rotational bonds; PSA, polar surface area in Å2.
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weakly active to inhibit proliferation of cancer cell lines.
None of the compounds showed hydrogen bonding
interaction with Glu-118. This may be attributed to the
absence of hydrogen bond donors on the phenyl ring of
DHPMs. Bioisosteric replacement of thiourea ‘S’ with
urea ‘O’ in the synthesized compounds appeared to be
oriented in similar fashion and retained similar interac-
tions as monastrol. Co-crystallized S-monastrol when
redocked in the active site of KSP attained a score of
−9.78 kcal/mol. It displayed vital H-bonding interactions
(−0.25495 kcal/mol) with the residues Glu-116 and
Glu-118 (Figure 3).
The most active compounds, 3 h against HepG2
(Figure 1) and compound 3 g against HeLa, fitted best in
the active site of Eg5 inhibitor protein and attained the
score of −7.541568 kcal/mol and −8.667402 kcal/mol,
respectively. It retained all the prime interactions to an-
chor well in the active sites of the receptor, except the
missing hydrogen bonding with Glu-118. Moreover,
hydrophobic interactions were observed to be involved
in the binding of the most active compounds. All active
compounds (compounds 3b, 3d, 3 g and 3 h) of the
DHPM series were oriented in the active site of the pro-
tein in a way that places the aromatic ring into the
pocket comprising the residues Glu-118, Arg-119, Trp-
127, Pro-137 and Tyr-211. On the other hand, the ethyl
group of S-monastrol and the cyclic amine substituents of
DHPMs were almost pointed towards aqueous environ-
ment (Table 3).
The virtual physicochemical parameters of the synthe-
sized compounds were benchmarked against standard
monastrol, and none of the descriptors were found toviolate the optimal range of the parameters required for
anticancer drugs. All the compounds validated Lipinski's
rule of five, which extends the scope of performance
in the in vivo studies. This shows the potential of
the compounds to bind with the enzyme effectively
and inhibit cell proliferation with minimized toxic
effects. Optimal pharmacokinetic properties such as
lipophilicity and absorption were established by the
QLogP values and polar surface areas, which corre-
lated with the number of hydrogen bond donors/
acceptors (Table 4).
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Eg5 represents a promising target, and designing Eg5 inhi-
bitors would offer a novel approach to develop potent
anticancer agents. A series of 12 novel monastrol analogs
based on Biginelli reaction were synthesized with IC50 in
the range of 120 to 398 μg/mL against HeLa and HepG2
cell lines. This new series consisted of pyrrolidine, piperi-
dine and morpholine as privileged structures attached to
the side chain of Biginelli dihydropyrimidinones through
amide bond to improve the metabolic stability. SAR ana-
lysis and molecular modeling studies revealed that the
positioning of a hydrogen bond donor/acceptor on the
phenyl ring of the dihydropyrimidinone plays a crucial
role in the inhibition of Eg5 enzyme to exhibit anticancer
activity. Although the new compounds were found to have
moderate to weak activity against cancer cell lines, the
reported results are expected to contribute toward deeper
insight into structure-activity relationship and could be
helpful in further designing dihydropyrimidinones as po-
tential anticancer agents.
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